Clinical trials: Alzheimer's Disease Dementia
Dementia, Dementia Alzheimer Type
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
This is a human clinical study making a noninvasive measurement from a patient's eye to determine whether there is a quantitative difference in measurements between patients with and without the diagnosis of dementia.
- Trial name
- DLS (NCT06613971)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- MD Stem Cells
Amyloid, Medullary Thyroid Cancer
Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis
Using excess tumour samples that contain amyoid, from patients with Medullary Thyroid Cancer, we aim to determine the structures of ex vivo amyloid fibrils from human tumour tissue samples and compare them with that of existing…
- Conditions
- Amyloid, Medullary Thyroid Cancer, Alzheimer Disease, Dementia
- Trial name
- NCT04760171
- Volunteers
- 10 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Alzheimer Disease
Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment (MCI)
In the ADDITION-MCI project, patients with a diagnosis of mild cognitive impairment probably caused by Alzheimer's disease will receive plasma exchange.
- Trial name
- ADDITION-MCI (NCT06234436)
- Testing
- Plasma exchenge
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Oslo University Hospital
Alzheimer Disease
Neuropsychological and Neurophysiological Effects of Cognitive Stimulation in Patients With Alzheimer's Disease and Mild Cognitive Impairment
The present study aims to evaluate the effect of cognitive stimulation (CS) in participants with a diagnosis of moderate and mild Alzheimer's disease (AD) and mild cognitive impairment (MCI) compared to control subjects not…
- Trial name
- NCT03784183
- Testing
- Cognitive Stimulation (CS)
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- University of Roma La Sapienza
Alzheimer's Disease (AD), Older Adults (65 Years and Older)
Improv Music Therapy for Older Adults
Older adults and their care partners will participate in music therapy sessions for approximately 8 weeks. Before and after the 8 week study period, participants will fill out questionnaires about their mood, stress levels, and…
- Trial name
- NCT07419022
- Testing
- Clinical Improvisation
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Alzheimer Disease
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo.
- Trial name
- NCT03446001
- Testing
- TRx0237 16 mg/day, Control, TRx0237 8 mg/day
- Where
- 103 sites in United States, Belgium and 6 more
- Volunteers
- 598 people
- Sponsor
- TauRx Therapeutics Ltd
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Diabetes Mellitus, Alzheimer Dementia
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
The purpose of this project is to study brain imaging of a substance called tau, which is found in brains of persons with Alzheimer's disease, using the Tau binder, 18F-THK-5351, for live imaging of tau in the brain.
- Trial name
- TAUPET (NCT03024944)
- Testing
- 18F-THK-5351
- Where
- United States
- Sponsor
- Columbia University
Alzheimer's Disease
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition…
- Trial name
- AD (NCT02947893)
- Testing
- Nilotinib Capsule(s) Once a Day by Mouth
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Georgetown University
Alzheimer Disease, Alzheimer' Disease
A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment…
- Trial name
- NCT06885567
- Testing
- BEY2153
- Where
- 3 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- BeyondBio Inc.
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm…
- Trial name
- NCT07762092
- Testing
- No Intervention
- Where
- 17 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Alzheimer Disease, Early Onset, Alzheimer Disease
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and…
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type
- Trial name
- EOAD-Subtype (NCT03153371)
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Cognitively Normal Older Adults, Hypertension
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau…
- Conditions
- Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
- Trial name
- IPAT (NCT05331144)
- Testing
- Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Rong Zhang
Alzheimer Disease
Effects of Transcranial Direct Current Stimulation Associated With Cognitive Training in Alzheimer's Disease
Alzheimer's disease (AD) is characterized by a progressive decline in cognitive functions, interfering with autonomy and independence.
- Trial name
- NCT04220593
- Testing
- tDCS associated with Tcog
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Federal University of Paraíba
Alzheimer's Disease
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
The purpose of this study is to evaluate the safety and tolerability of dimebon given to Alzheimer's disease patients currently on a stable dose and regimen of memantine or memantine plus donepezil.
- Trial name
- NCT00829816
- Testing
- Dimebon
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Medivation, Inc.
Obesity, Bariatric Surgery Candidate
BE Smart - Bariatric Patient - Empowerment in the Preparation and Follow-up of Bariatric Surgery Using the Smartvisit App (BESmart)
Obesity affects an increasing proportion of the population and is associated with numerous comorbidities that cause increased morbidity and mortality. The most effective therapy for morbid obesity is metabolic bariatric surgery.
- Trial name
- BESmart (NCT06061406)
- Testing
- smart visit app
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Wuerzburg University Hospital
Alzheimer Disease, MCI
Detecting an MCI and Amyloid Digital Neuro Signature(DNS) Using Altoida's Multimodal Digital Biomarkers.
The purpose of this study is to establish multiple points of clinical validity for the Altoida digital biomarker assessment in individuals with a clinical diagnosis of cognitively normal (CN) and Mild Cognitive Impairment (MCI).
- Trial name
- NCT06223438
- Where
- United States
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Altoida
Alzheimer's Disease
Memantine - Communication Study
The study objective is to evaluate the effects of memantine treatment on communication abilities and other cognitive abilities in moderate to severe DAT patients.
- Trial name
- NCT00624026
- Testing
- Memantine-HCl
- Where
- Germany
- Volunteers
- 107 people
- Sponsor
- Merz Pharmaceuticals GmbH
Parkinson's, Alzheimer Disease
Sound Estimation and Accuracy Task
Participants will be assigned to complete computerized estimation tasks for which there is a component of accuracy, such as estimating the duration of sounds.
- Trial name
- NCT02271685
- Testing
- Instructions about Overestimates, Instructions about Parkinson's, Instructions about Underestimates
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Carnegie Mellon University
Alzheimer's Disease
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind…
- Trial name
- NCT02586909
- Testing
- RVT-101 35 mg tablets
- Where
- 169 sites in United States, Argentina and 17 more
- Volunteers
- 1,099 people
- Sponsor
- Axovant Sciences Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.